DeFronzo R A, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J
J Clin Invest. 1981 Feb;67(2):563-8. doi: 10.1172/JCI110067.
Tissue sensitivity to insulin was examined with the euglycemic insulin clamp technique in 17 chronically uremic and 36 control subjects. The plasma insulin concentration was raised by approximately 100 microU/ml and the plasma glucose concentration was maintained at the basal level with a variable glucose infusion. Under these steady-state conditions of euglycemia, the glucose infusion rate is a measure of the amount of glucose taken up by the entire body. In uremic subjects insulin-mediated glucose metabolism was reduced by 47% compared with controls (3.71 +/- 0.20 vs. 7.38 +/- 0.26 mg/kg . min; P less than 0.001). Basal hepatic glucose production (measured with [3H]-3-glucose) was normal in uremic subjects (2.17 +/- 0.04 mg/kg . min) and suppressed normally by 94 +/- 2% following insulin administration. In six uremic and six control subjects, net splanchnic glucose balance was also measured directly by the hepatic venous catheterization technique. In the postabsorptive state splanchnic glucose production was similar in uremics (1.57 +/- 0.03 mg/kg . min) and controls (1.79 +/- 0.20 mg/kg . min). After 90 min of sustained hyperinsulinemia, splanchnic glucose balance reverted to a net uptake which was similar in uremics (0.42 +/- 0.11 mg/kg . min) and controls (0.53 +/- 0.12 mg/kg . min). In contrast, glucose uptake by the leg was reduced by 60% in the uremic group (21 +/- 1 vs. 52 +/- 8 mumol/min . kg of leg wt; P less than 0.005) and this decrease closely paralleled the decrease in total glucose metabolism by the entire body. These results indicate that: (a) suppression of hepatic glucose production by physiologic hyperinsulinemia is not impaired by uremia, (b) insulin-mediated glucose uptake by the liver is normal in uremic subjects, and (c) tissue insensitivity to insulin is the primary cause of insulin resistance in uremia.
采用正常血糖胰岛素钳夹技术,对17例慢性尿毒症患者和36例对照者的组织胰岛素敏感性进行了检测。通过可变葡萄糖输注,将血浆胰岛素浓度提高约100微单位/毫升,并将血浆葡萄糖浓度维持在基础水平。在这种正常血糖的稳态条件下,葡萄糖输注速率是全身摄取葡萄糖量的一个指标。与对照组相比,尿毒症患者胰岛素介导的葡萄糖代谢降低了47%(3.71±0.20对7.38±0.26毫克/千克·分钟;P<0.001)。尿毒症患者基础肝葡萄糖生成(用[3H]-3-葡萄糖测量)正常(2.17±0.04毫克/千克·分钟),胰岛素给药后正常抑制94±2%。在6例尿毒症患者和6例对照者中,还通过肝静脉插管技术直接测量了内脏葡萄糖净平衡。在吸收后状态下,尿毒症患者(1.57±0.03毫克/千克·分钟)和对照者(1.79±0.20毫克/千克·分钟)的内脏葡萄糖生成相似。持续高胰岛素血症90分钟后,内脏葡萄糖平衡恢复为净摄取,尿毒症患者(0.42±0.11毫克/千克·分钟)和对照者(0.53±0.12毫克/千克·分钟)相似。相比之下,尿毒症组腿部葡萄糖摄取减少了60%(21±1对52±8微摩尔/分钟·千克腿部重量;P<0.005),这种减少与全身总葡萄糖代谢的减少密切平行。这些结果表明:(a)尿毒症不损害生理性高胰岛素血症对肝葡萄糖生成的抑制作用;(b)尿毒症患者肝脏胰岛素介导的葡萄糖摄取正常;(c)组织对胰岛素不敏感是尿毒症胰岛素抵抗的主要原因。